Literature DB >> 24744635

Early profound secondary autoimmune thrombocytopenia induced by clopidogrel in a patient with a coronary artery stent.

Volkan Karakuş1, Burak Deveci1, Erdal Kurtoğlu1, Sakir Arslan2.   

Abstract

Entities:  

Year:  2012        PMID: 24744635      PMCID: PMC3986780          DOI: 10.5505/tjh.2012.59244

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

TO THE EDITOR

Clopidogrel in combination with aspirin is commonlyused for the prevention of thrombosis in patients with coronaryartery stents [1]. Moreover, since being introducedclopidogrel has proven to be very safe, tolerable, and efficacious[2]. Indications for clopidogrel use are expanding,and include reduction of such cardiovascular events asmyocardial infarction and stroke in appropriate patients.As the use of clopidogrel increases, uncommon side effectsare encountered more frequently [3]. Autoimmune thrombocytopeniais an extremely rare adverse effect of clopidogreltherapy [4]. We report a case of autoimmune thrombocytopeniarelated to standard clopidogrel treatment in apatient 2 days after coronary stenting. A 63-year-old male presented with acute inferior myocardialinfarction, which was treated with primary stenting;heparin was administered periprocedurally. Thepatient was given aspirin (300 mg d–1 p.o.) and clopidogrel(75 mg d–1 p.o.), and 2 days later he developed diffusepetechiae that prompted evaluation. Physical examinationdid not reveal any signs of splenomegaly. Laboratory findingswere as follows: platelet count: 7 x 109 L–1; hemoglobin:13.4 g dL–1; leukocyte count: 4.7 x 109 L–1. Peripheralblood smear showed severe thrombocytopenia withoutmicroangiopathic changes. The lactate dehydrogenaselevel, prothrombin time, and activated partial thromboplastintime were normal. The diagnosis of clopidogrelassociatedautoimmune thrombocytopenic purpura wassuspected. Clopidogrel and aspirin were discontinued at the timeof application. Intravenous methylprednisolone (1 g) wasgiven daily. A total of 2 units of platelets were transfusedin the first day of treatment. The patient responded in thethird day of high dose steroid therapy, with stabilizationof the platelet count (45 x 109 L–1) and no new petechiae.According to the guidelines of The American Society ofHematology, bone marrow biopsy and aspiration were notperformed because bone marrow examination is not recommendedin cases of isolated thrombocytopenia highlysuspicious for the diagnoses of immune thrombocytopenicpurpura [5]. Aspirin was subsequently resumed in thethird day of high dose steroid therapy and high dose steroiddiscontinued then oral methylprednisolone 1mg/kgwas administered. 6 days later the platelet count was 132x 109 L–1 while on oral steroid therapy Written informedconsent was obtained from the patient for publication. Thrombocytopenia is a rare, but dangerous adverseeffect of clopidogrel, and encompasses thrombotic thrombocytopenicpurpura (TTP), isolated thrombocytopenia,and autoimmune thrombocytopenia [2]. Autoimmunethrombocytopenic purpura is an immune regulation disorderin which autoantibodies cause platelet destruction[6]. Treatment targets the prevention of splenic plateletdestruction, using such medications as corticosteroids,intravenous immunoglobulin, and azathioprine. Splenectomyis indicated when medical therapy fails [3]. The presentedpatient responded to high-dose steroid treatment.The patient’s response to steroid therapy confirmed anautoimmune etiology, which together with the time framesuggested it was unlikely to have been related to heparin.Careful monitoring for hematologic adverse effects followingclopidogrel use is essential for prompt diagnosis andtreatment of this potentially life-threatening complication.

CONFLICT OF INTEREST STATEMENT

The authors of this paper have no conflicts of interest,including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materialsincluded.
  6 in total

1.  Is there delayed restenosis in patients with coronary artery disease treated with sirolimus-eluting stent?

Authors:  Jian-Jun Li; Bo Xu; Yue-Jin Yang; Ji-Lin Chen; Shu-Bing Qiao; Wei-Hua Ma; Xue-Wen Qin; Min Yao; Hai-Bo Liu; Yong-Jian Wu; Jin-Qing Yuan; Jue Chen; Shi-Jie You; Jun Dai; Ran Xia; Run-Lin Gao
Journal:  Coron Artery Dis       Date:  2007-06       Impact factor: 1.439

Review 2.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

Review 3.  Autoimmune (idiopathic) thrombocytopenic purpura.

Authors:  S Karpatkin
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

4.  Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration.

Authors:  Yuan-Lin Guo; Jian-Jun Li; Jin-Qing Yuan; Xue-Wen Qin; Xin Zheng; Chao-Wei Mu; Yi-Hong Hua
Journal:  World J Cardiol       Date:  2010-06-26

Review 5.  Hematologic adverse effects of clopidogrel.

Authors:  Saravanan Balamuthusamy; Rohit Arora
Journal:  Am J Ther       Date:  2007 Jan-Feb       Impact factor: 2.688

6.  Clopidogrel-associated autoimmune thrombocytopenic purpura.

Authors:  Patricia J M Best; Verghese Mathew; Svetomir N Markovic
Journal:  Catheter Cardiovasc Interv       Date:  2004-07       Impact factor: 2.692

  6 in total
  1 in total

1.  The change in platelet count in patients with acute coronary syndrome 6 months after coronary stent implantation.

Authors:  Zhanqiang Zhang; Lihong An; Dayong Du; Xiaohui Lai; Fang Wang; Yuntian Li
Journal:  Blood Coagul Fibrinolysis       Date:  2015-09       Impact factor: 1.276

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.